Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically Confirmed Non Small Cell Lung Cancer.
Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).
Chemotherapy with regimens containing cisplatin or carboplatin is mandatory
Response to combined therapy
You may not be if
No previous treatment with ZD1839 or any other EGFR-targeted therapy
No progressive disease after combined therapy for locally advanced NSCLC
No presence of metastatic disease
No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
Any unresolved chronic toxicity from previous anticancer therapy.
Clareo Health | Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC
